Predict your next investment

Corporation
defiante.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

About Defiante Farmaceutica

Defiante Farmaceutica operates as a pharmaceutical company based in Portugal.

Defiante Farmaceutica Headquarter Location

Portugal

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Defiante Farmaceutica Investments

2 Investments

Defiante Farmaceutica has made 2 investments. Their latest investment was in RegeneRx Biopharmaceuticals as part of their PIPE on December 12, 2006.

CBI Logo

Defiante Farmaceutica Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/21/2006

PIPE

RegeneRx Biopharmaceuticals

$9.55M

Yes

3/21/2002

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/21/2006

3/21/2002

Round

PIPE

Unattributed VC

Company

RegeneRx Biopharmaceuticals

Subscribe to see more

Amount

$9.55M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

0

Defiante Farmaceutica Portfolio Exits

1 Portfolio Exit

Defiante Farmaceutica has 1 portfolio exit. Their latest portfolio exit was Questcor Pharmaceuticals on August 15, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/15/2014

Acq - P2P

$99M

2

Date

8/15/2014

Exit

Acq - P2P

Companies

Valuation

$99M

Acquirer

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.